Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. METHODS: We used double immunostaining to evaluate pathway activation in the mammalian target of rapamycin complex (mTORC) and the nature of cell proliferation in the vessels of patients with primary or secondary antiphospholipid syndrome nephropathy. We also evaluated autopsy specimens from persons who had catastrophic antiphospholipid syndrome. The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway were evaluated in vitro, and potential pharmacologic inhibitors were also tested in vitro. Finally, we studied the effect of sirolimus in kidney-transplant recipients with the antiphospholipid syndrome. RESULTS: The vascular endothelium of proliferating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications of activation of the mTORC pathway. In cultured vascular endothelial cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Patients with antiphospholipid syndrome nephropathy who required transplantation and were receiving sirolimus had no recurrence of vascular lesions and had decreased vascular proliferation on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirolimus. Among 10 patients treated with sirolimus, 7 (70%) had a functioning renal allograft 144 months after transplantation versus 3 of 27 untreated patients (11%). Activation of mTORC was also found in the vessels of autopsy specimens from patients with catastrophic antiphospholipid syndrome. CONCLUSIONS: Our results suggest that the mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome. (Funded by INSERM and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and subsequent mTOR activation occurs in various rheumatic diseases257–259.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [257]
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,543
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Research works printed but not linked: 1
- Alarcon-Segovia D, 1989, J Rheumatol, 16, 762
Cited by
Items 301–365 of 365
Quoi de neuf en Médecine interne ?
Laffitte, E. (2014) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(14)70165-6 · Cited by 1
Acquired Coagulation Disorders
Kruczek, K. R., Cooper, K. A., Mai, H., & Nand, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-27327-3_8 · Cited by 1
Wei, Y., Cai, S., Ding, J., Zeng, Y., Yin, T., & Diao, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90805-4.00021-3 · Cited by 1
Inoue, K., Hori, S., Fujii, K., Sakamoto, K., Tomizawa, M., Morizawa, Y., Gotoh, D., Nakai, Y., Yoneda, T., & Fujimoto, K. (2023) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.56.143 · Cited by 1
Novel Pyrazino[2,3-b] Pyrazines as mTOR Kinase Inhibitors for Treating Cancer and other Diseases
De, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230726112328 · Cited by 1
Pediatric antiphospholipid syndrome
Petrović, G., & Pašić, S. (2023) · Medicinski podmladak · doi:10.5937/mp74-42885 · Cited by 1
Heart valve involvement in antiphospholipid syndrome: More than you think!
Zuily, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.021 · Cited by 1
Taghavi, M., Demulder, A., Mesquita, M. D. C. F., Dernier, Y., Nortier, J., Collart, F., & Pozdzik, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1606215/v1 · Cited by 1
Pericleous, C., Stuckey, D. J., Maughan, R. T., Paschalaki, K. E., Kabir, L., Bourke, L., Willis, R., Rahman, A., RANDI, A. M., Arachchillage, D. J., et al. (2024) · medRxiv · doi:10.1101/2024.01.04.24300876 · Cited by 1
“Both the APS nephropathy study and a second in vivo thrombosis model study implicate dysregulation of Akt and its signalling mediators in endothelium, but in opposing ways – suggesting activation 24 and inhibition 37 respectively.”
BackgroundPathogenesis of antiphospholipid antibody syndrome
Tohidi‐Esfahani, I., Cohen, H., Ioannou, Y., & Giles, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00037-x · Cited by 1
Taghavi, M., Jacobs, L., Laureys, M., & Nortier, J. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2486566 · Cited by 1
“APS-associated vasculopathy involves endothelial dysfunction and the activation of the mammalian Target of Rapamycin (mTOR) complex 1 pathway, which plays a central role in cell proliferation, remodeling and intimal hyperplasia, a key processes in restenosis [5].”
Conceptos de hemostasia, trombofilia y síndrome antifosfolípido
Orozco-López, G., Rubio-Jurado, B., & Nava-Zavala, A. H. (2015)
Korth, R.-M. (2016) · Health · doi:10.4236/health.2016.83026
“Obese women are at higher risk for antiphospholipid syndromes based on endogenous formation of antibodies against adverse carrier proteins initiating then a dramatic inflammatory cross talk between endothelium and smooth muscle cells with accelerated risk for thrombotic events [42] [43].”
BackgroundAntiphosphatidylethanolamine Antibodies: New Pieces to the Puzzle of the Antiphospholipid Syndrome?
Zaratzian, C., Zypinoglou, J., Morange, P., & Bardin, N. (2015) · Journal of Arthritis · doi:10.4172/2167-7921.1000169
Anticorps anticardiolipine et anti-bêta 2 glycoprotéine 1
Bardin, N. (2017)
Fact checking the lore of hypercoagulable work up
Shen, Y.-M. P. (2017)
Effect of Thrombophilic Factors on Renal Graft Function: A Single-Center Experience
Furmańczyk-Zawiska, A., Bączkowska, T., Dęborska−Materkowska, D., Nazarewski, S., Kosieradzki, M., & Durlik, M. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.02.096
An unusual case of heart attack
Young, J. K.-Y., & Ng, D. K. H. (2018) · Hong Kong bulletin on rheumatic diseases · doi:10.2478/hkbrd-2018-0004
Síndrome de anticuerpos antifosfolípidos
Francès, C., & Chasset, F. (2018) · EMC - Dermatología · doi:10.1016/s1761-2896(18)92423-4 · Cited by 1
Atteinte artérielle du syndrome des antiphospholipides
Zuily, S., Siddique, S., & Wahl, D. G. (2016) · Elsevier eBooks · doi:10.1016/b978-2-294-74970-4.00074-9
Rand, J. H., & Wolgast, L. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00141-4 · Cited by 2
Mechanisms of Antiphospholipid Syndrome Induction: Role of NKT Cells
Ширшев, С. В. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919090025
Zespół antyfosfolipidowy — opis przypadku i przegląd literatury
Antkowiak-Piatyszek, K. (2019) · Forum Reumatologiczne · doi:10.5603/fr.2019.0015 · Cited by 1
“Przeciwciała antyfosfolipidowe biorą też udział w aktywacji szlaku mTOR, prowadząc do przerostu błony środkowej naczynia, a w konsekwencji do waskulopatii będącej jedną z przyczyn zamykania naczyń tętniczych w nerkach [22].”
Ocampo, C. R., Gutiérrez, L. A., Padilla, L. M. R., Navas, M. A. M., Franco, C. J. V., Gutiérrez-Marín, J. H., & Campo, M. N. C. (2020) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2020.06.003
Autoantibodies and Kidney Diseases
Topaloğlu, R., Levart, T. K., Nagata, M., & Avčin, T. (2021) · Springer eBooks · doi:10.1007/978-3-642-27843-3_98-1
Zuo, Y., & Knight, J. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00021-x
Tratamento de SAF baseado na Força Tarefa Internacional
ANDRADE, D. C. O. D., & Lopes, M. R. U. (2018) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2018.17.2.28-31
Coronary Artery Embolism and Antiphospholipid Syndrome: A Case Report and Review of the Literature
Liu, Y., Li, D., Xu, T., Patiway, E., Alim, G., Tong, C., Zhao, J., Rozi, P., Hayrilla, E., & Wang, Z. (2020) · Clinical Cardiology and Cardiovascular Interventions · doi:10.31579/2641-0419/116
“mTOR inhibitors such as sirolimus may be especially useful in APS patients with AMI requiring percutaneous intervention (PCI) to decrease in-stent vascular proliferation occurring several months after stent implantation [25].”
BackgroundChan, T. M., & Yung, S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732868595.793576806
(2014) · Kidney International · doi:10.1038/ki.2014.340
Autoantibodies and Kidney Diseases
Topaloğlu, R., Levart, T. K., Nagata, M., & Avčin, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_98
Raccis, M., Dossi, F., Bernardelli, A., Aste, M., Berisso, G., & Parodi, G. (2023) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001219
Jiang, H., Li, M. L., Zhao, J. L., & Zhao, Y. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14820
Severe cutaneous necrosis in antiphospholipid syndrome
Mostafa, M. A. O., Mahmoud, A. A., Egiza, H., Niu, C., Elbahnasawy, M., Yusuf, Y., & Kouides, P. A. (2023) · American Journal of Hematology · doi:10.1002/ajh.27067
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation
Jiang, H., Shi, Y., Liu, W., Liu, B., Chen, Y., Zhou, Y., Huang, C., Wang, Q., Tian, X., Zhao, Y., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2023-003664
Étude du rôle de REST dans les podocytes au cours du vieillissement et du stress cellulaire
Magassa, S. (2019) · theses.fr (ABES) · doi:10.70675/7c83076az15d3z4a47za6e7zce812a1e9831
Lupus Erythematosus and Antiphospholipid Syndrome
Dutz, J. P., & Khosravi‐Hafshejani, T. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook051
Metabolic control of immunopathogenesis in systemic lupus erythematosus
Perl, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00023-x
Skin involvement in other autoimmune diseases
Xu, Y., Tian, J., Chen, J., Hu, Q., & Zhu, H. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00062-x
Varotto, L., Spigolon, L., Dotto, A., Leonardi, D., Bragantini, G., Cerrito, L. F., Deluca, C., & Hoxha, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164732
“The most recognized theory illustrates the role of uncontrolled complement activation with an identifiable precipitating event such as infection, surgery or pregnancy [13,14].”
BackgroundSíndrome de anticuerpos antifosfolípidos
Chasset, F. (2024) · EMC - Dermatología · doi:10.1016/s1761-2896(24)49754-9
Torun, E. S. (2024) · Medical Research Archives · doi:10.18103/mra.v12i12.6128
Syndrome des anticorps antiphospholipides
Chasset, F. (2026) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/j.fander.2026.06.002
Autophagic Flux Might Be Blocked in Patients With Primary Antiphospholipid Antibody Syndrome
Tang, K.-T., Chen, Y.-H., Wang, J.-H., Hsieh, T.-Y., Chao, Y.-H., Chen, D., Chen, H.-H., & Lin, C.-C. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70063
(2025) · Thieme Medical Publishers eBooks · doi:10.1055/b-0044-207667
Álvarez, D., Winter, H. E., Markert, U. R., J., Á. P. C., & Prieto, D. M. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1702103
Catastrophic Antiphospholipid Syndrome
Gris, J., Chéa, M., & Pérez‐Martin, A. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2765-9663
“…inhibition, although this remains uncertain Working on the intimal vascular hyperplasia accompanying the most severeformsofAPS, Canaud et al 54 found indications that the endothelial mammalian target of the rapamycin complex (mTORC) pathway was activated; the aPL Abs-mediated effect being…”
The Intersection of Blood Vessel Inflammation in Autoimmune and Metabolic Disease
Solomon, J. L., Piccione, J., Gulkarov, S., Srivastava, A., Leon, J. D., Belilos, E., Carsons, S. E., & Reiss, A. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-55254-0_24-1
Liu, H., Wang, Y., Cai, Y., Guo, R., Liu, S., Chen, T., Sun, T., Huo, R., Liu, T., Lv, Q., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504027
“Canaud et al. [37] later demonstratedthat aPL-β 2 GPI bindingacti-vates PI3K–AKT–mTORC signaling, triggering aberrant endothelial proliferation, vascular wall thickening, lumen narrowing, and tissue ischemia.”
Makhdoom, H. Q., Sandokji, I. A., Almutairi, Y. H., Alahmadi, K. I., Almohammdi, M. S., Almoutairi, B. A., Alhamawi, R. M., & Mahallawi, W. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093269
“The uremic milieu is known to promote both apoptosis (through oxidative stress and accumulation of uremic toxins such as indoxyl sulfate and p-cresyl sulfate) and ferroptosis (through iron dysregulation and depletion of glutathione peroxidase 4) [28,29].”
Avčin, T., & Monagle, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11980-4.00029-5
Gaspar, P., Ribeiro, F., Fonseca, V. R., Romão, V. C., Fonseca, J. P. A., & Graça, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104112
Pathogenesis of antiphospholipid syndrome
Hisada, R., Amengual, O., & Atsumi, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00062-7
Kazbennaou, I., Laban, T., Frimat, M., Moal, V., Bertrand, D., Claisse, G., Couzi, L., Costedoat-Chalumeau, N., François, H., Grimbert, P., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.07.013
Diffuse alveolar hemorrhage in primary antiphospholipid syndrome: A case series of six patients
Doubková, M., Štefániková, M., Buliková, A., Ivaničová, T., & Doubek, M. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101313
Pan, H., Wei, X., Gu, S., Fan, Y., Yang, Z., Yu, S., Qian, J., Li, X., Wu, J., Zhou, T., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.08.017
Martins, M., Cruz-Machado, A. R., Barreira, S. C., Barinotti, A., Radin, M., & Sciascia, S. (2026) · Future Rare Diseases · doi:10.1080/23995270.2026.2737657
Nuevas estrategias de tratamiento para el síndrome antifosfolipídico
Poveda-Paredes, F. X., León-Pallasco, D. A., Paredes-Tobar, O. S., & Coque, E. J. P. (2026) · CIENCIAMATRIA · doi:10.35381/cm.v12i6.3360
Metadata
- Authors
- Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., Legendre, C., & Terzi, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 303-312
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151319957
- Cited by
- 355
- References
- 38
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 34 · 2023: 29 · 2022: 22 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 44 · 2017: 33 · 2016: 34 · 2015: 25 · 2014: 7
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- antiphospholipid syndrome, rapamycin, antiphospholipid antibodies, PI3K/Akt signaling, vascular endothelial cell proliferation, kidney transplantation, catastrophic antiphospholipid syndrome, renal allograft survival, vascular lesions
- MeSH terms
- Adult, Analysis of Variance, Autopsy, Endothelium, Vascular, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, Kidney, Kidney Diseases, Male, Middle Aged, Kidney Transplantation, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Sirolimus, Cell Proliferation, Metabolic Networks and Pathways, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.